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Abstract
A switch in the conformational properties of a-synuclein (aS) is hypothesized to be a key step in the pathogenic mechanism
of Parkinson’s disease (PD). Whereas the beta-sheet-rich state of aS has long been associated with its pathological
aggregation in PD, a partially alpha-helical state was found to be related to physiological lipid binding; this suggests a
potential role of the alpha-helical state in controlling synaptic vesicle cycling and resistance to b-sheet rich aggregation. N-
terminal acetylation is the predominant post-translational modification of mammalian aS. Using circular dichroism,
isothermal titration calorimetry, and fluorescence spectroscopy, we have analyzed the effects of N-terminal acetylation on
the propensity of recombinant human aS to form the two conformational states in interaction with lipid membranes. Small
unilamellar vesicles of negatively charged lipids served as model membranes. Consistent with previous NMR studies using
phosphatidylserine, we found that membrane-induced a-helical folding was enhanced by N-terminal acetylation and that
greater exothermic heat could be measured upon vesicle binding of the modified protein. Interestingly, the folding and
lipid binding enhancements with phosphatidylserine in vitro were weak when compared to that of aS with GM1, a lipid
enriched in presynaptic membranes. The resultant increase in helical folding propensity of N-acetylated aS enhanced its
resistance to aggregation. Our findings demonstrate the significance of the extreme N-terminus for folding nucleation, for
relative GM1 specificity of aS-membrane interaction, and for a protective function of N-terminal-acetylation against aS
aggregation mediated by GM1.
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Introduction
The conformational plasticity of a-synuclein (aS), a cytosolic
protein abundant in neurons, erythrocytes and endothelial cells
[1], has been associated with differential physiological and
pathophysiological properties. Intraneuronal aggregates consisting
of aSi nab-sheet-rich conformation, called Lewy bodies and
neurites, are a pathological hallmark of Parkinson’s disease (PD)
and several related human brain disorders.
We and others recently reported that aS unbound to lipids can
exist in the cytosol in an a-helical, oligomeric state that is much
more resistant to aggregation than the unfolded monomer [2–4].
The exact folding and oligomerization pathway that leads to these
helical oligomers in vivo is not known. The induction of a-helix
formation of aS in its unfolded monomeric state in vitro has been
shown to be mediated inter alia by its binding to small unilamellar
vesicles (SUV) composed of negatively charged lipids [5]; lipid
binding and folding leads to protection of aS from pathology-
associated misfolding [6], which suggests the existence of a
beneficial folding pathway of the physiological form of the protein.
Lipid interaction has been shown to be particularly strong for the
neuronal monosialoganglioside, GM1 [7]. It also has been
reported that the extreme N-terminus of aS is important for lipid
interaction and membrane-induced helix formation [8–10].
Recent reports indicate that all detectable aS in vivo is post-
translationally modified by an acetyl group attached to the a-
amino group of the first N-terminal amino acid [2,11,12]. Despite
this knowledge, most in vitro studies of aS have been performed
on recombinantly expressed protein lacking this physiologically
meaningful modification. N-alpha-acetylation (NAA) has been
implicated in stabilizing helical conformations among the ensem-
ble of unfolded aS conformations in vitro [13] as well as leading to
the formation of folded, oligomeric aS [14], which resembles the
recently discovered aggregation-resistant forms of native aS
isolated from cells [2,15]. Given the apparent importance of
NAA for the conformational landscape of aS and its interaction
with lipids, we performed systematic biophysical analyses of the
impact of the acetyl group on the thermodynamics of aS folding
and lipid binding, and we explored how the pathology-associated
properties of aS may be affected. We employed isothermal
titration calorimetry in tandem with CD spectroscopy to dissect
the thermodynamic parameters associated with membrane bind-
ing and the concomitant coil-helix transition of aS with versus
PLOS ONE | www.plosone.org 1 July 2014 | Volume 9 | Issue 7 | e103727without N-terminal acetylation. We found that the N-terminal
acetyl group enhanced general membrane binding and mediated a
relative specificity of aS for the neuronal ganglioside GM1.
Interestingly this enhanced interaction led to a complete resistance
to fibrillar aggregation of acetylated aS but not of the non-





sialoganglioside GM1 and GM3 (both bovine) were purchased
from Matreya LLC (Pleasant Gap, PA) as dry powder. All other
chemicals were obtained from Sigma-Aldrich unless otherwise
noted.
Protein Preparation
A construct based on the sequence of human aS in pET5a was
used to transform Escherichia coli BL21(DE3). For N-acetylated
aS, the bacteria were co-transformed with a pACYCduet plasmid
containing cDNA encoding for both catalytic (Naa20) and
regulatory (Naa25) subunits of the fission yeast NatB complex, a
generous gift by Daniel Mulvihil (University of Kent, UK).
Bacterial cultures were induced with isopropyl-b-D-thiogalacto-
pyranoside for 4 h, and lysed by sonication in 20 mM Tris buffer,
pH 8.0, 25 mM NaCl. The lysate was quickly microwaved to
boiling in order to denature common proteases, and then kept at
65uC for 30 min to precipitate heat unstable proteins quantita-
tively. The supernatant of a 20 min 20,0006g spin was further
processed. For non-denaturing purification, the boiling step was
replaced by a 50% (NH4)2SO4 precipitation step, and the pellet
was taken up in 20 mM tris buffer, pH 8.0, 25 mM NaCl. The
sample was injected onto a 5-ml HiTrap Q HP anion exchange
column (GE Healthcare, Pittsburgh, PA), equilibrated with
20 mM Tris buffer, pH 8.0, 25 mM NaCl. aS was eluted from
the column with a 25–1000 mM NaCl gradient in 20 mM Tris
buffer, pH 8.0. Peak fractions were pooled and further purified via
gel filtration on a Superdex 200 column (GE Healthcare,
Pittsburgh PA) with 50 mM ammonium acetate pH 7.4 as
running buffer. The peak fractions were lyophilized and N-
terminal acetylation was validated by mass spectrometry.
Isolation of aS from human erythrocytes
The purification was conducted as described previously [2]. For
a detailed description please see http://www.nature.com/
protocolexchange/protocols/2136.
CD spectroscopy
Spectra were recorded with a Jasco 815 spectropolarimeter
(Jasco Inc., MD). A cuvette with 1 mm path length was filled with
200 mL of the protein solution. The proteins were titrated with
phospholipid vesicles using a micro pipet with gel loading tip for
lipid addition and mixing of the protein and vesicle solutions.
Control spectra obtained with titrations of vesicle suspensions in
buffer alone were subtracted from the experimental spectra.
Temperature control with an accuracy of +/20.5uC in the cuvette
was achieved with a heating/cooling accessory using a Peltier
element. The helicity of the protein (i.e. the percentage of the
entire protein sequence in an a-helical state) was obtained from
the mean residue ellipticities, H222, according to fhelix=(H222–
Hcoil )/( Hcoil – Hhelix) where % helicity=100 fhelix. Here the mean
residues ellipticities at 222 nm for the completely unfolded and
completelyfoldedpeptideswereobtainedfromHcoil=640–45T/uC
and Hhelix=–40000(1–2.5/n) + 100T/uC, where n is the number of
amino acids in the polypeptide [16].
Isothermal Titration Calorimetry
Isothermal titration calorimetry measurements were performed
with an iTC200 instrument (MicroCal, Amherst, MA). Typically,
18 lipid suspension injections of 2 mL each (+1 pre-injection with
0.4 ml) were titrated into the calorimeter chamber containing
200 mL of the protein solution. Control injections of vesicles into
buffer alone were performed and used for baseline subtraction.
The data were processed using the MicroCal ORIGIN 5.0
software, and thermodynamic parameters were determined from
the sigmoidal titration curves with the assumption that there are
independent saturable binding sites in the vesicle interface. The
ligand concentration was equated with the total lipid concentra-
tion in the syringe; the aggregation state of the lipids and the
accessibility of the inner lipid bilayer of the unilamellar vesicles
were neglected. N independent lipid binding sites on the protein
were assumed. Incremental heat values DQ=Qi-12 Qi were
calculated and the experimental data was fitted by variation of N
and the microscopic binding constant Kb’, as well as the
microscopic enthalpy change DH’ according to the standard
Marquard-Levenberg algorithm [17]. This yields the enthalpy per
mole of protein, and a single macroscopic binding constant Kb
through DH
0=NDH’ and Kb=NKb’, as well as the free energy
(DG




binding reaction with respect to the protein.
Vesicle Preparation
Mixtures of phospholipids were first taken up and mixed in tert-
butanol. After overnight lyophilization, the lipid mixtures were
hydrated for 30 min at 25uC in 1 mL of buffer containing 10 mM
ammonium acetate, pH 7.4. Small unilamellar vesicles were
prepared by pulse-sonicating the phospholipid suspensions for
20 min at 4uC with a microtip sonicator (Fischer Sonic
Dismembrator Model 300, Thermo Scientific, MA, USA). The
translucent vesicle solutions were spun down at 15,0006g for
10 min to pellet any remnants of solid metal particles. Quality
control of the vesicles was performed using a Malvern Dyna Pro
dynamic light scattering instrument (Westborough, MA), which
showed uniform vesicles with a mean diameter of about 30 nm.
ThT fluorescence assay
a-Synuclein fibrils were formed by incubating 0.6 mg/ml
protein in the presence of 50 mM ammonium acetate at
pH 7.4. Aliquots of 2.5 mL of the solution were added to
197.5 mLo f1 0mM thioflavin T in 10 mM glycine at pH 9.0
[18], and the fluorescence intensity was recorded at 485 nm with
excitation at 447 nm in a Synergy H1 plate reader (Biotek,
Winooski, VT).
Results
Variable changes in aS secondary structure upon
N-acetylation
We recently discovered the existence of a helically folded
oligomeric form of endogenous aS in human cells, an observation
that has led to an ongoing controversy in the field. The main
origin of this controversy is that the protein had previously been
characterized as ‘‘natively unfolded’’, based principally on studies
of recombinantly expressed aS purified from bacterial lysates. This
seemed to disagree directly with our characterization of the
protein isolated under non-denaturing conditions from human
cells. A major difference between aS obtained from these two
GM1 Binding of Alpha-Synclein
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the human protein, a post-translational modification found
commonly in mammalian proteins. We therefore first examined
the effect of NAA on the overall folding of bacterially expressed aS
in the absence of structure-inducing detergents or lipids, in
comparison with aS isolated from fresh human red blood cells
(RBC-aS). To this end, we co-expressed aS in bacteria with the
fission yeast complex N-acetyltransferase B (NatB), which is
reported to cause targeted NAA of other recombinantly expressed
proteins that share with aS the N-terminal amino acid motif Met-
Asp (MD) [19]. In order to preserve any structure induced by the
NAA, we used a non-denaturing protocol to purify the bacterially
expressed recombinant protein. This method generated prepara-
tions that were 100% N-a-acetylated aS (NAA-aS), as confirmed
by mass spectrometry (data not shown). As shown by circular
dichroism (CD) spectra, we obtained some batches of a-helically
folded NAA-aS in the absence of detergent (e.g. the BOG used by
Trexler et al. [14]) or lipids (Fig. 1A), and such preparations
contained minor amounts of SDS-stable oligomeric NAA-aS
(Fig. 1B), in agreement with a recent report by Trexler et al. [14]
and closely resembling endogenous RBC-aS. However, in other
batches ostensibly prepared identically under non-denaturing
conditions, we observed mainly unfolded NAA-aS, similar to the
NAA-aS preparations reported by Fauvet et al. [20], and yet other
preparations were folded in an intermediate state (Fig. 1A). Even
the maximally unfolded preparations had a slightly higher a-
helical content than comparable preparations of aS obtained
without co-expression of NatB (approximately 9% vs 5% helicity
measured by CD spectroscopy). This increased helicity could not
be prevented by application of heat denaturation (data not shown)
and thus appeared to be an intrinsic property of NAA-aS
independent of the purification method. It is important to note
that no such variability in the amount of helical content was
observed for bacterial preparations of aS without N-acetylation
under non-denaturing conditions; it was all unfolded with only
minor helical content (5%). The cause(s) of the conformational
variability in the recombinant batches of NAA-aS prepared under
seemingly identical conditions are under investigation but
currently remain elusive. None of the variations in the temperature
during IPTG induction (25 or 37uC), cell density at harvest
(OD600: 0.8–1.5) or the IPTG concentration used for induction
(0.1–1 mM) had a clear correlation with helicity. It has to be noted
though that preparations with higher helical content typically had
lower overall protein yield and that N-terminally acetylated aS
seemed to be more resistant to N-terminal degradation during the
purification procedure in general. Given the lack of control over
batch variability under non-denaturing conditions, we decided to
analyze separately the properties of the invariably mostly unfolded
NAA-aS obtained under denaturing conditions in regards to its
interaction with lipids in order to gain more insight into possible
folding mechanisms of this post-translationally modified form of
aS. We therefore used a heat denaturation step in our purification
protocol for both NAA-aS and non-acetylated aS in all
experiments described below to obtain maximally unfolded
protein preparations. This denaturation step allowed us to control
variability in helical content and assess the impact of N-terminal
acetylation on initiation of in vitro folding upon in interaction with
lipids.
Folding Initiation of NAA-aS by Negatively Charged Lipid
Vesicles
Lipid vesicles bearing a net negative surface charge have been
reported to bind monomeric aS associated with a concomitant
conformational transition from random coil to a-helix [5,7]. Such
vesicles were therefore chosen to study the impact of the NAA
modification on helix formation. Three model lipids were chosen:
phosphatidylserine (PS), for its abundance in neuronal membranes
[21] and to compare the resultant data to previous studies [13];
GM1 ganglioside, for its reported specific interaction with aS [7];
and GM3 as a control lipid to test the specificity of N-acetylation
for the headgroup of GM1. We prepared mixtures of each of these
lipids (20%) with phosphatidylcholine (PC, 80%) due to the lack of
interaction of aS with PC [22] and the inability of PS or GM1 to
form stable small unilamellar vesicles (SUV) on their own. We
tested for structure induction by titrating increasing amounts of the
lipids into the aS protein solutions (typically 5 mM) and assessing
conformational changes by far-UV circular dichroism (CD)
spectroscopy. In tandem, we detected the thermodynamic changes
by isothermal titration calorimetry (ITC) with identical protein
concentrations and lipid mixtures. Figures 2A and B show
titrations of PS-containing POPC vesicles (POPC/POPS 4:1) into
protein solutions of NAA-aS measured by CD. The coil-helix
transition can be conveniently followed by spectroscopic measure-
ment of CD at a wavelength of 222 nm. As seen in Fig. 2A, a
decrease of the ellipticity (arrow) is indicative of an increasing
conformational change towards a-helical secondary structure; this
characteristic allows us to readily compare the induction of
secondary structure for aS by plotting the decrease of ellipticity at
222 nm for a given aS/lipid ratio. To account for slight differences
in aS concentration between measurements, we show here the
measured CD signal as the mean residue ellipticity (MRE, H).
In Figs. 2B, C and D, the CD titration curves for aS and NAA-
aS during interaction with PS, GM3 or GM1 are shown. The
initial slopes of the MRE versus the lipid/protein molar ratio plots
for PS titration into solutions of aS vs. NAA-aS are nearly
identical, suggesting that their interaction with the negatively
charged headgroup of PS is very similar (Fig. 2B). While a small
difference in average MRE between aS and NAA-aS can be
detected for a given PS concentration, this is also seen in the
absence of lipids; this result indicates that there is a higher general
baseline of a-helical content for NAA-aS. The titration endpoints
where maximum ellipticity is achieved converge, implicating a
very similar amount of maximal secondary structure (approx. 44%
a-helix; see Methods) at a PS-to-synuclein ratio of 80:1 for both
NAA-aS and aS. This value is almost identical to the approx. 46%
helical content that can be found in natively purified human RBC-
aS tetramers [2]. This result in agreement with previous studies by
Maltsev et al. [13] and Dikiy et al. [23], but the differences seem
small when compared to experimental variability seen in between
different measurements. Interestingly, titrations with vesicles
containing the gangliosides GM3 and GM1 showed a decreased
barrier to folding initiation for both forms of aS when compared to
PS (Figs. 2C and D) and thus a much stronger effect of N-
acetylation was observed than before for PS. Since all three lipid
types have the same net charge, the results imply that the folding
nucleation by the interaction of the aS N-terminus with the
gangliosides is specifically strengthened, possibly through hydro-
gen bonds between the acetylated protein and the sugars in the
headgroups. Both aS and NAA-aS achieved maximum folding at
lipid-to-protein ratios of about 60:1 when titrated with GM3
vesicles. However, titrations with the negatively-charged ganglio-
side GM1 gave a significantly steeper slope for NAA-aS than aS,
suggesting an increased conformational sensitivity to lipid contact
by NAA-aS. In the presence of GM1 containing SUVs, the
ellipticity of NAA-aS reaches a constant value at lipid/protein
ratios of 40:1, while a higher ratio (55:1) is needed for maximum
structure induction in non-acetylated aS (Fig. 2 D). As the only
structural difference between GM1 and GM3 can be found in the
GM1 Binding of Alpha-Synclein
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acid, this directly points at an interaction of the N-acetyl group of
the protein with the oligosaccharide chain of the lipid, which leads
to a decreased activation barrier for helical folding.
Impact of N-Acetylation on the Thermodynamics of Lipid
Interaction
To assess quantitatively the thermodynamics of the lipid-aS
interaction, we employed ITC. ITC offers many advantages over
other techniques because the heat signal measured is a nearly
universal property of chemical binding reactions as well as of the
physical adsorption processes. ITC provides the opportunity to not
only measure accurately the binding constant of the protein-lipid
association, but also dissect the contributions of thermodynamic
parameters such as enthalpy or entropy to the process of
adsorption and folding.
Fig. 3A shows aliquots of PS SUVs titrated into a calorimeter
cell containing solutions of aS. The negative heat-exchange upon
vesicle injection shows that the lipid-protein interaction is
exothermic. After integration of the obtained heat signals, a
binding or partition curve can be derived. As seen in Figs. 3B–D,
the titration curves show a classic sigmoidal shape reminiscent of
what would be observed in a specific ligand-protein interaction,
not a partition equilibrium that one would expect in simple
membrane insertion of a polypeptide. Thus, we assumed the
presence of uniform saturable lipid binding sites on both aS and
NAA-aS and evaluated the data accordingly (see Methods). We
summarize all of the biophysical parameters obtained by ITC and
CD in Table 1.
The fitting results for PS vesicles indicate a comparable binding
constant (KB) and hence comparable free energy (DG0) for aS and
NAA-aS, demonstrating a very small effect size of N-terminal
acetylation, in agreement with recent literature [13,23]. However
this comes as a surprise given that slightly lower binding for NAA-
aS was expected due to the elimination of the positive charge at
the alpha-amino group by acetylation and the resultant slight
decrease in the electrostatic interaction between the positively
charged N-terminus of the unmodified protein and the negatively
charged headgroup of the lipid. The calculated total enthalpy of
the lipid-protein interaction for both forms of synuclein is
approximately 0.4–0.5 kcal/mol per amino acid residue of the
lipid binding N-terminal region aa1–94 [24], which is in the
expected range for membrane insertion and secondary structure
formation [25]. The contributions of enthalpy (DH0) and entropy
(DS0) are similar for aS and NAA-aS, with the lipid interaction of
NAA-aS being more exothermic (Table 1). Both interactions are
enthalpy driven and are counterbalanced by a loss in entropy,
probably due to the formation of secondary structure and
restricted diffusion of lipids around the protein binding sites. This
effect is larger for NAA-aS than for aS, indicating a slightly larger
amount of helical conformation in NAA-aS, as seen in the
respective CD spectra in Figures 2B and C. The inflection point of
the titration curve at a lipid/protein ratio of 70:1 is in agreement
with the CD data, showing a beginning saturation of protein
binding accompanying helix formation.
These differences are again exaggerated in the interaction with
GM3. As can be seen from Figs. 3C and D, the interaction of aS
with ganglioside in general leads to greater heat release compared
to the titration with PS. The more exothermic reaction of NAA-aS
points to an increased interaction of the acetyl group with GM3
and PS. The gain of heat release in the presence of NAA-aSi s
comparable between GM3 and PS, however indicating a lack of
specificity of the N-acetylation for either of these lipids. As the
position and slope of the inflection point of the binding curves is
seemingly identical between NAA-aS and aS, the increased heat
Figure 1. Variability in the folding of purified recombinant NAA-aS under non-denaturing conditions. A: CD spectroscopy of bacterially
expressed and purified NAA-aS and aS under non-denaturing conditions. No variability in the secondary structure was seen with unmodified aS. In
contrast, NAA-aS showed batch-to-batch variability in folding of the obtained preps. B: SDS-PAGE Western blot and Coomassie stain of aS and NAA-
aS (‘‘expression C’’). The samples were not boiled in SDS-sample buffer before gel loading for Western blotting. The NAA-aS banding pattern
indicates some SDS-stable tetrameric protein present in the sample, while no higher bands could be detected in non-acetylated aS. For coomassie
staining, the samples were boiled in sample buffer, leading to a single stainable band at 14 kDa, indicative of the high purity of the sample.
doi:10.1371/journal.pone.0103727.g001
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tighter binding in general. It could be assumed that the additional
heat release is due to increased structure formation in either the
protein or the lipid membrane.
As shown in Fig. 3D, the titration curves for GM1-containing
vesicles show a markedly different thermodynamic profile between
aS and NAA-aS. While the calculated free energy (DG0) and
binding constants (KB) are closely similar within the limits of
experimental variation (Table 1), the total enthalpy (DH0)
measured upon NAA-aS-GM1 interaction is approx. 255 kcal/
mol, about twofold of the 28 kcal/mol detected for non-modified
aS. This strong exothermic process is compensated by a loss in
entropy (DS0T), which is again twofold larger for NAA-aS than for
aS. Analysis of the inflection points of both titration curves
Figure 2. Structural change induced in aS vs. NAA-aS by negatively charged vesicles. A: Example of CD spectroscopy of PS vesicles
titrated into NAA-aS solutions at 25uC. Spectra are shown at ascending lipid/protein ratios. Note the isobestic point (at 204 nm) indicative of a pure
two state coil-helix transition. The arrow indicates the decrease in ellipticity at 222 nm as a consequence of helical folding. B–D: CD spectroscopy
measurements of aS( 5mM) titration with PS (POPC/POPS 4:1, 40 mM) (B), GM3 (POPC/GM3 4:1, 40 mM) (C) and GM1 (POPC/GM1 4:1, 40 mM) (D).
Decrease in MRE at 222 nm upon titration of aS with PS, GM3 and GM1 containing vesicles correlates with increased a-helical structure in either NAA-
aS or non-acetylated aS.
doi:10.1371/journal.pone.0103727.g002
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PLOS ONE | www.plosone.org 5 July 2014 | Volume 9 | Issue 7 | e103727Figure 3. ITC-measured heat release curves of NAA-aS and aS upon titration with negatively charged lipid vesicles. A: Example of
primary heat signal obtained from titration calorimetry of PS vesicles titrated into solutions of NAA-aSa t2 5 uC measured in tandem with the CD
spectra in Fig. 2. B: Integrated heat signals of titrations of PS vesicles (POPC/POPS 4:1, 40 mM) into protein solutions of NAA-aS and aS( 5mM). The
sigmoidal titration curve suggests simple protein-lipid binding with saturable binding sites. C: Titrations of GM3 vesicles (POPC/GM3 4:1, 40 mM) into
solutions of NAA-aS and aS( 5mM) at 25uC. D: Titration of GM1 vesicles (POPC/GM1 4:1, 40 mM) vesicles into the two protein solutions (5 mM). Note
the doubled heat release for NAA-aS compared to non-acetylated aS. All measurements were conducted at 25uC.
doi:10.1371/journal.pone.0103727.g003
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NAA-aS and aS, although the number is slightly higher for the
acetylated form (35 for NAA-aS vs. 31 for aS). Given the small
contribution of the electrostatic interaction to the total enthalpy
[26] this slight increase in the average in bound lipid should not
account for the entire twofold change in enthalpy and entropy.
The increased heat release upon lipid binding can be easily
visualized when the cumulative obtained heat is plotted against the
amount of titrated lipid. As seen in Fig. 4A, each single lipid
titration leads to an increased exothermic reaction when the N-
terminal acetyl group is present. This is surprising, as both forms of
the protein have similar lipid binding constants. However, the heat
measured by ITC must be treated as a composite quantity that
summates interfacial binding and structure formation in the
protein. A linear relationship was found between the cumulative
heat released by vesicle binding and the MRE at 222 nm, which
indicates that the energy transfer is associated with an equivalent
increment in secondary structure formation (MRE) (Fig. 4B).
While the correlations of titrations with PS and GM3 vesicles
were almost identical for both aS variants (data not shown), in the
case of GM1, the slopes of the linear regression lines are almost
twice as great for NAA-aS than for aS. The MRE reaches similar
values for all 3 lipids and thereby demonstrates a very similar helix
formation. This phenomenon suggests that the large exothermic
heat observed upon NAA-aS-GM1 interaction cannot be solely
explained by the electrostatic binding of aS to the membrane
vesicle surface and the accompanying coil-helix transition. The
larger release of exothermic heat with a decrease in entropy must
rather be accounted for by structure induction other than a-helix
formation in the protein. This could be through increased
clustering of GM1 lipids around the bound protein or additional
tertiary or quaternary structure formation of NAA-aS at the
membrane interface. The additional formation of structure would
also explain the larger comparative loss of entropy that accom-
panies lipid interaction (247 and 220 kcal/mol for NAA-aS and
aS, respectively).
Inhibition of aS Aggregation by both N-Acetylation and
GM1 Interaction
Inhibition of aS b-sheet-fibrillation by lipid vesicles [6] and the
presence of helical secondary structure [2,3] have been reported to
be potential modulators of pathogenic aS aggregation; this
suggests that the slightly higher helicity of NAA-aS can mediate
resistance to aggregation. We agitated NAA-aSo raSa ta
concentration of 0.6 mg/ml at 37uC, conditions that had been
optimized to detect small changes in aggregation propensity while
maintaining manageable time frames. In order to asses the amount
of helix induction and amount of protein bound to lipid under
these exact conditions, we repeated CD and ITC measurements
with both NAA-aS and aS for GM1 at 37uC, obtaining KB and
MRE values identical to experiments conducted at 25uC (data not
shown). Using a thioflavin T aggregation assay, we monitored the
aggregation for 8 days. The fibrillation of NAA-aS and aS were
measured as an increase in fluorescence intensity of the thioflavin
T dye upon binding to b-sheet-rich aggregates that had formed in
the samples over time. As seen in Fig. 5, pure protein solutions of
NAA-aS displayed slower aggregation kinetics compared to those
of pure aS as reported in the literature [27] and expected from
higher helical content of the sample. To test the effect of lipid
association in combination with acetylation, we conducted
experiments in parallel in the presence of POPC/GM1 SUV at
a protein/lipid ratio of 1:10, a molar ratio that only induces a
minor increase in helical structure of both NAA-aS and aS
(Fig. 2). The incubation with GM1 vesicles led to a delay from 4 to
8 days in the time necessary for maximal fibril formation of non-
acetylated aS in accordance with previous studies [7]. This effect
was more pronounced with NAA-aS in that the addition of GM1
SUV seemingly led to a complete prevention of thioflavin-positive
aggregation, at least for the 8 days of the experiment (Fig. 5). A
possible explanation for this cumulative effect of GM1 interaction
and acetylation could be the small but significant increase in
helicity measured under these conditions for NAA-aS when
compared to non-acetylated aS (Fig. 2). This would indicate that
even a small population of GM1-bound aS can contribute to
stabilizing helical conformations that raise the energetic barrier for
refolding into beta-sheet and thus protects the whole ensemble of
different conformations that must occur in solution due to rapid
exchange. Alternatively, a small difference in binding affinity
detected for NAA-aS and GM1 (Table 1) could lead to a slightly
smaller concentration of non-lipid bound NAA-aS which could
slow self-association in the free form of the protein.
Discussion
We and others recently reported the existence of an abundant
tetrameric form of aS in human cells [2,4] and in an N-terminally
extended recombinant construct [3] that is helically folded and
relatively resistant to amyloid aggregation. This finding was in
stark contrast to numerous reports characterizing recombinantly
expressed aS as a ‘‘natively unfolded’’ monomer (e.g. [28]). The
finding has led to studies either disputing it [29] or independently
Table 1. Thermodynamic and structural parameters for NAA-aS and aS upon SUV titration.
DH0 kcal/mol KB 610
6 M
-1 DS0T kcal/mol DG0 kcal/mol Helicity % Bound lipids/aS
aS n/a n/a n/a n/a 5 (10) n/a
+ PS 237.2+/21.3 4.6+/21.2 228.1+/21.9 29.1+/20.5 44 (95) 56+/25
+ GM3 231.3+/22.5 5.8+/21.3 222.0+/23.6 29.2+/20.7 44 (95) 41+/26
+ GM1 228.2+/22.7 0.8+/21.9 220.2+/25.6 28.8+/20.5 44 (95) 31+/25
NAA-aS n/a n/a n/a n/a 9 (19) n/a
+ PS 248.4+/23.4 4.0+/22.3 239.4+/23.1 29.0+/20.5 43 (95) 59+/24
+ GM3 238.6+/25.1 2.8+/22.4 229.8+/25.9 28.8+/20.4 44 (95) 36+/28
+ GM1 255.2+/26.5 1.23+/22.1 246.9+/26.4 28.3+/20.2 45 (96) 35+/28
Experiments were performed at 25uC. Depicted values are means values from 3 independent measurements with standard deviations shown for the ITC measurements.
Helicity values are means from 3 independent measurements.
doi:10.1371/journal.pone.0103727.t001
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part in murine brain tissue [30]. The presence of N-alpha-
acetylation in endogenous human aS then became a focus of
study, since it seemed to be the principal post-translational
modification (PMT) distinguishing recombinantly expressed and
endogenous cellular aS. One study showed that this PMT alone
can be responsible for the formation of helically-folded oligomers
under certain conditions [14]. While we were able to find some
evidence for the latter finding in that we isolated some helically
folded and apparently tetrameric aS from bacteria expressing aS
plus N-acetyl-transferase complex B (Fig. 1), our findings imply
that N-acetylation alone is necessary but insufficient for the
formation of helical tetramer. The variability in this result led us to
investigate systematically the effect of N-acetylation on aS folding
initiation. By studying the lipid assisted folding of aS, we may
thereby gain more insight into the potential mechanism of helical
tetramer formation in vivo. Although recent studies have been
investigating the impact of N-acetylation on helical folding of aSi n
the presence of lipid, observing slightly increased interaction with
phosphatidylserine [13] in agreement with our data, the strong
and apparently specific effect of the interaction of the extreme N-
terminus with GM1 ganglioside has not been reported heretofore.
Prior work demonstrated the ability of aS to bind small
unilamellar lipid vesicles, with a concomitant random coil-to-helix
transition when in contact with negatively charged lipids [5,31,32].
This lipid interaction has been associated with stabilization of
vesicular plasticity and the control of vesicle fusion [33–36] as well
as the inhibition of fibril formation [7]. Such results suggest the
importance of mutual structure stabilization of membrane and
protein in normal cellular function. Our new results here support
the increased propensity of aS toward lipid binding and helical
folding upon N-acetylation, a post-translational modification that
seems to be present in the large majority of endogenously
expressed aS molecules in human tissue [2,11,12]. Starting with
phosphatidylserine, the model lipid classically used to induce
helical folding in aS [5] and used to test the effect of N-acetylation
[13], we probed for differences in lipid binding and secondary
structure formation.
Phosphatidylserine showed little preference for interacting with
NAA-aS over the non-acetylated protein. Whereas titrations of PS
vesicle solutions showed minimal but measurable effects of N-
terminal acetylation on alpha-helix induction, an analysis of the
thermodynamic parameters by ITC revealed a slightly elevated
heat release for NAA-aS. This is in agreement with previous
studies that also recorded a small but detectable effect of N-
terminal acetylation upon interaction with PS. These results are
surprising, given that the removal of a positive charge from the
extreme N-terminus seems not to lessen but to strengthen the
interaction with the negatively charged membrane surface. The
same was generally true for the ganglioside GM3, even though the
interaction with the sugar headgroup led to a much greater
exothermic heat release and increased folding initiation for both
aS and NAA-aS when compared to PS. This could indicate a
better hydrophobic match between the now less charged N-
terminus and the acyl chains of the lipid, possibly by a deeper
intrusion of the amphipathic helix into the hydrophobic core of the
bilayer [37].
Interestingly, we show here that the N-acetylation seems to
specifically strengthen the interaction between NAA-aS and GM1.
Not only does the N-terminal acetylation apparently promote
secondary structure formation upon GM1 binding, but the
thermodynamics of the binding event are also altered by the
presence of the acetyl group, leading to an almost twofold increase
in heat release of NAA-aS over unmodified aS.
Aggregation of aS into amyloid fibrils has been centrally
implicated in the pathogenesis of Parkinson’s disease. In this
Figure 4. Characterization of synuclein-GM1 interaction. A. Cumulative reaction enthalpy of aS vs. NAA-aS (each at 5 mM) upon vesicle
titration with GM1 vesicles is shown as a function of lipid/protein ratio. Experiments were conducted at 25uC. Note the strongly increased heat release
for NAA-aS upon titration with GM1. B. ITC-CD correlation plots showing the different interactions of NAA-aS and aS with GM1 vesicles. The
interaction of NAA-aS and aS with GM1 vesicles is shown as correlation of MRE at 222 nm (abscissa) with corresponding cumulative heat release
(ordinate). The greater slope obtained for NAA-aS indicates an increased heat release accompanied by similar secondary structure induction.
doi:10.1371/journal.pone.0103727.g004
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NAA-aS leads to enhanced aggregation resistance, with fibril
formation being undetectable by our Thioflavin T fluorescence
assay in the presence of GM1. aS can be found in lipid raft and
raft-like regions of the synapse, where it co-localizes with GM1
[38] and from which it can be released during synaptic activity
[39]. We speculate that binding to GM1-rich membranes could
therefore protect monomeric aS from pathogenic aggregation
despite its leading to a higher local concentration of aS at the
membrane interface. It is interesting to note that while the familial
PD-associated aS mutations A53T and A30P have been reported
to accelerate aggregation [40,41], the mutation A30P has also
been reported to disrupt membrane interaction and helix folding
[42]. Considering membrane binding and helix formation as a
possible protective mechanism, we suggest that N-terminal
acetylation and the A30P mutations may work in opposite
directions; while A30P accelerates disease relevant mechanisms,
NAA decelerates it, especially in the presence of GM1 ganglioside.
An extensive body of literature can be found on the potential
involvement of GM1 gangliosides in the pathogenesis of PD [43],
through either accelerated aS aggregation in mice having
decreased GM1 levels [44,45] or a decrease in PD-type symptoms
upon administration of GM1 [46,47]. There is also evidence for a
connection between Parkinson’s disease and disorders with
defective glucocerebroside metabolism like Gaucher’s disease that
indirectly affect GM1 levels [48]. Our findings here could provide
an explanation for an apparent correlation between the presence
of excess GM1 and the moderation of synuclein-dependent
neuronal dysfunction.
In summary, our data suggests that the overall effect of the N-
terminal acetylation should not be neglected in studying the
function or biochemical/biophysical properties of aS. Given the
apparent absence of non-acetylated aS in mammalian tissues
[2,11,12], we believe it is imperative to use NAA-aS in future
in vitro studies, in order to reduce artifacts arising from
recombinant expression and not miss any meaningful changes in
the highly complex folding landscape of this disease-relevant
protein.
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Figure 5. N-alpha acetylation has a functional impact on aS aggregation into amyloid fibrils. Aggregation of NAA-aS and aS (0.6 mg/ml)
in the absence or presence of GM1 containing vesicles (GM1/protein 10:1 mol/mol) measured by an increase in thioflavin T fluorescence. Standard
deviations are calculated from N=4 experiments. The presence of N-acetylation or GM1 vesicles binding each led to increased resistance to
aggregation, with the effects being cumulative. A 2-way ANOVA test was used to test for significance at selected time points. ****=p,0.0001.
doi:10.1371/journal.pone.0103727.g005
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